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The local ethics committees in Irvine and Berlin approved the studies for the initial and 
confirmatory cohorts, respectively. Patients in the confirmatory study consented for use of their 
data outside the respective trials, in which their data was acquired. Studies were conducted in 
conformity with the 1964 Declaration of Helsinki in its currently applicable version, following 
Good Clinical Practice guidelines. All study participants gave written informed consent. 
Clinical Scoring 
Clinical examination was performed according to Kurtzke’s Expanded Disability Status Scale 
(EDSS).1 Additionally, disability was assessed using the MS Functional Composite (MSFC), 
comprising the timed 25-ft walk test (T25FW), the 9-hole peg test (9-HPT) and the 3-second Paced 
Auditory Serial Additions Test (PASAT).2 MSFC z-scores were calculated according to the MSFC 
Administration and Scoring Manual. MS Severity Scores (MSSS) were calculated from disease 
duration and EDSS.3 
Magnetic Resonance Imaging (MRI) 
MRI was performed at 1.5 Tesla using three-dimensional T1-weighted magnetization prepared 
rapid acquisition and multiple gradient echo sequences (MPRAGE; T1w) and axial T2-weighted 
(T2w) sequences. Images were either acquired on a Sonata MRI (Siemens Medical Systems, 
Erlangen, Germany) with TE 4.38ms, TR 2,110ms, TI 1.1ms, flip angle 15° and isotropic 
resolutions 1 mm3 for T1w, and multiecho TSE with TE 81ms, TR 5,780ms, 150° flip angle, 
resolution 0.5x0.5x3mm3, no gap for T2w, or on an Avanto MRI (Siemens Medical Systems, 
Erlangen, Germany) with TE 3.09ms, TR 1,900ms, TI 1.1ms, flip angle 15° and isotropic 
resolutions 1mm3 for T1w, and 3D TSE with TE 175ms, TR 3,000ms, flip angle 120°, isotropic 
resolutions 1mm3 for T2w.  
Thalamic volume was determined as summary volume from both hemispheres using FIRST (FSL 
5.0, FMRIB Software Library, Oxford, UK)4 on MPRAGE scans and normalized using a brain-
size normalization factor output from FSL SIENAX (FSL, FMRIB Software Library, Oxford, 
UK)5 for each individual brain. Brain volumes were determined using MPRAGE scans with the 
FSL 5.0 pipeline SIENAX. For pre-processing, MRI were cropped to a robust field of view and 
registered to MNI standard space implemented in FSL with subsequent correction for bias field 
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non-uniformity using the N3-algorithm in the MIPAV package version 5.4.2. SIENAX computes 
global brain volume (NBV) as well as grey matter (NGMV) and white matter (NWMV) volume 
estimates normalized with respect to the individual’s head size, accounting for inter-individual 
variability. Two-time point percentage brain volume change (PBVC) was estimated with SIENA, 
part of FSL,5 in those patients for which 18-month follow-up data was available. Patients with 
pathological PBVC were determined by established cutoff of 0.52% annual loss (95% specificity).6 
Optical Coherence Tomography (OCT) 
Retinal nerve fiber layer thickness (RNFL) from both eyes was measured with a Stratus OCT, 
software version 4.0 (Carl Zeiss Meditec, Dublin, CA, USA) using the fast RNFL 3.4 protocol as 
previously described.7 Patients were examined without pupil dilation. Only images with acceptable 
quality were included in the analysis, defined as visually even signal distribution, a reflectance 
signal strong enough to identify the RNFL layer borders, correct centration, and signal strength of 
≥7 of 10. Images with erroneous RNFL segmentation were excluded from analysis. 
Targeted Liquid chromatography - tandem mass spectroscopy (LC-MS/MS)   
All serum samples were analyzed in a blinded fashion by the central mass spec laboratory in 
Toronto. The operator performing the measurements (JP) was not involved in study design or 
informed about the scientific objectives. Results were then sent to the main investigators, who 
performed statistical analysis. Serum samples for metabolomics analysis were prepared as 
described previously.8 Briefly, 50 µL serum (stored at -80oC) and 200µl ice cold extraction solvent 
(40% acetonitrile: 40% methanol: 20% H2O), were vortexed for 2 minutes, then shaken in an 
Eppendorf shaker (Thermomixer R) at 1400 rpm, 4°C for 1 hour and centrifuged at 4°C for 10 
minutes at ~18,000 x g in an Eppendorf microfuge. Supernatants were transferred to a clean tube 
and evaporated in a Speedvac (Acid-Resistant CentriVap Vacuum Concentrators, 
Labconco).  Dried samples were stored at -80°C.  Samples were resuspended in 100 µl of water 
containing the Internal Standards D7-Glucose at 0.2 mg/mL and H-Tyrosine at 0.02 
mg/ml.  Samples were resolved by LC-MS/MS, in negative mode at the optimum polarity in MRM 
mode on an electrospray ionization (ESI) triple-quadrupole mass spectrometer (AB Sciex 
4000Qtrap, Toronto, ON, Canada). MultiQuant software (AB Sciex, Version 2.1) was used for 
peak analysis and manual peak confirmation.  The results, expressed as area ratio (area of 
analyte/area of internal standard), were exported to Excel, and analyzed with MetaboAnalyst 3.0.30 
Standard curves were prepared by adding increasing concentrations of GlcNAc or N-Acetyl-D-
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[UL-13C6]glucosamine ([UL
13C6] GlcNAc) (Omicron Biochemicals, Indiana) to 50 µl aliquot of 
control serum (Fig. 1B). This way we were able to create a calibration curve for HexNAc serum 
levels, obtaining absolute values rather than relative concentrations (Fig. 1C). Analysts were 
blinded in regard to sample origin (control or patient). 
Statistical Analysis 
Statistical analyses were performed with R Project version 3.5.3. Sample sizes were based on 
convenience samples. Correlation between age or sex and serum HexNAc levels were analyzed 
with linear regression models for age and Welch’s t-test for sex in HC. Group differences between 
HC, RRMS and PMS patients were analyzed using linear models with age as covariate. To 
combine results of group comparisons in the discovery and confirmatory cohorts, we used Fisher’s 
combined probability test, which combines p-values using their logarithmic transformation. 
Association between treatment status and serum HexNAc was assessed by the Kruskal-Wallis 
test. For boxplots, the solid middle line represents the median. The lower and upper hinges 
correspond to the 25th and 75th percentiles. The upper and lower whisker extends from the hinge 
to the distant value no further than 1.5*IQR from the hinge (where IQR is the inter-quartile range, 
or distance between 25th and 75th percentiles). Receiver Operating Characteristics curves (ROC) 
were used to quantify serum HexNAc’s ability to discriminate between RRMS and PMS. 
Correlations between serum HexNAc level and clinical scores or imaging parameters were 
analyzed using linear regression models with HexNAc serum level as an independent parameter, 
except for EDSS and lesion measurements, which were analyzed using non-parametric 
Spearman’s Rho analyses (EDSS because of the measure’s ordinality, and lesion measurements 
because of their non-normal or skewed distributions i.e. as count variables). RNFL correlations 
were analyzed with generalized estimating equation models (GEE) accounting for inter-eye 
within-patient effects and using serum HexNAc level as an independent parameter. All correlation 
analyses based on parametric models were corrected for age and sex. Partial R2 was calculated to 
only include serum HexNAc-attributable variance in these models. PBVC between month 18 and 
baseline was compared using linear models with baseline NBV, age and sex as covariate. Serum 
HexNAc concentration before and during oral treatment with GlcNAc were compared using one-
sided paired Wilcoxon signed-rank tests, comparing the mean of the weeks before treatment to the 
mean of the weeks under treatment. Data from discovery and confirmatory cohorts were examined 
for non-normal distributions by visual inspection of histograms and calculation of skewness and 
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kurtosis. In case data was missing, data was not amended (sample size is indicated in each figure). 
Significance in all tests was established at p<0.05, whereas a trend was considered in p<0.1. After 
initial two-sided testing of HexNAc serum concentration in HC and in RRMS vs. PMS patients, 
all further tests were one-sided testing an association of serum HexNAc levels with worse disease 
outcomes. 
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eTable 1. Discovery Cohort 
    HC RRMS PMS 
Subjects n 66 33 21 
PPMS n   2 
SPMS n   19 
Age (years) Mean (SD) 42 (20) 50 (11) 55 (7) 
Sex (M/F) n/n 28/38 8/25 7/14 
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eTable 2. Confirmatory Cohort 
    RRMS PMS 
Subjects n 125 55 
PPMS n  23 
SPMS n  32 
Age (years) Mean (SD) 40 (9) 49 (8) 
Sex (M/F) n/n 42/83 31/22 
Time since diagnosis (months) Mean (SD) 113 (81) 129 (101) 
EDSS Median (Min - Max) 2 (0-6) 6 (3-8) 
MSSS Mean (SD) 3.2 (2.3) 6.8 (1.7) 
    
T25FW (sec) Mean (SD) 5.02 (1.82) 11.24 (7.61) 
9-HPT dominant hand (sec) Mean (SD) 20.65 (5.39) 31.22 (16.81) 
9-HPT non-dominant hand (sec) Mean (SD) 20.99 (4.51) 32.50 (13.66) 
PASAT-3 (from 60) Mean (SD) 48.06 (11.98) 41.67 (11.92) 
    
Thalamus Volume (ml) Mean (SD) 13.72 (2.13) 14.83 (1.88) 
NBV (1,000 x ml) 
Mean (SD) 1,510,627 (84,548) 1,429,843 
(73,349) 
NGMV (1,000 x ml) Mean (SD) 765,433 (53,471) 711,502 (44,458) 
NWMV (1,000 x ml) Mean (SD) 745,193 (43,165) 718,341 (41,592) 
RNFL (µm) Mean (SD) 94.6 (13.4) 87.0 (11.4) 
 
 
